Loading…
The milestone marks significant progress in the trial for FAP treatment.
Biodexa Pharmaceuticals Plc announced that it has enrolled 100 patients in its registrational Phase 3 trial for Serenta, a treatment for Familial Adenomatous Polyposis (FAP). The announcement signifies a key milestone in the trial's progress.
The trial aims to evaluate the efficacy and safety of Serenta in treating FAP. With 100 patients now enrolled, the company is moving closer to completing the necessary data collection for regulatory submission.
Biodexa Pharmaceuticals Plc has a free float of 605,875 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.